Molecular genetic and epigenetic mechanisms of primary and secondary resistance to imatinib mesylate treatment in ph chromosome positive chronic myeloid leukemia patients

Imatinib mesylate (IM) is a BCR-ABL targeted tyrosine kinase inhibitor drug used for frontline therapy in patients with chronic myeloid leukemia (CML). IM is highly effective and is considered the standard of care in CML management. Even though IM has become the gold standard frontline treatment...

全面介绍

Saved in:
书目详细资料
主要作者: Elias, Marjanu Hikmah
格式: Thesis
语言:English
出版: 2015
主题:
在线阅读:http://eprints.usm.my/40418/1/Dr._Marjanu_Hikmah_Elias_PhD-24_pages.pdf
标签: 添加标签
没有标签, 成为第一个标记此记录!